This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA
Menu
keyboard_arrow_right

Main Conference - Day 2 (May 21)

keyboard_arrow_leftSearch & Filter
search
Main Conference - Day 2 (May 21)
search
Networking Refreshment Break in Poster and Exhibit Hall
Showing 1 of 1 Streams
10:10am - 10:20am
Comparative Analysis of Diastereomeric Distribution in siRNA Synthesis: Phosphoramidite Chemistry vs. Enzymatic Synthesis
  • Stephanie Forget, PhD - Senior Scientist, Protein Engineering, Codexis
10:20am - 10:30am
Multidimensional RNA Profiling for Therapeutic Development Success
  • Wayne Doyle - Head of Platform, Eclipse Bioinnovations
10:30am - 10:40am
Selectivity Enabling NanoShell, SENS(TM): Advancing Gene Therapy Development through Innovative Tissue-selective Delivery
  • Saudat Fadeyi, PhD, MBA - Head of Business Development and Strategy, Samyang Biopharm USA
Showing 1 of 1 Streams
1:10pm - 1:20pm
Scalable Drying of Thermosensitive TIDES in Solvents Using Electrostatic Drying (ESD)
  • Katherine Buzecky - Director of Scientific Services, Fluid Air
1:20pm - 1:30pm
Quality Control Strategy of Delivery Ligand of Galnac
  • Rocky Liu - International Business Director, Wuhu Huaren
1:30pm - 1:40pm
mRNA Manufacturing on the NMU-SymphonyTM - A Rapid End-to-end Platform for the Design, Microfluidic Synthesis, and Delivery of Personalized Cancer Therapeutics
  • Colin McKinlay, PhD - Senior Director, Chemistry and Delivery Technology, Nutcracker Therapeutics
1:40pm - 1:50pm
mRNA/LNP Projects - from Gene to IND and Beyond
  • Telmo Graça, PhD - Head of mRNA Process Development, Lonza
Networking Refreshment Break in Poster and Exhibit Hall
Showing 1 of 1 Streams
3:40pm - 3:50pm
Overcoming Impurities in Therapeutic APIs: Transforming Reagent Solutions for Solid and Liquid Phase TIDES Synthesis
  • Colin Smith - Innovation Leader, Pharma, Aurorium
3:50pm - 4:00pm
A Strategy to Develop Potential and Safe mRNA-based Therapeutics
  • Hamid Trimech - Business Development Manager, Arcalis
4:00pm - 4:10pm
Synthetic Peptide CMC Development and Experiences
Main Conference - Day 1 Keynote Sessions (May 20)
NextMain Conference - Day 3 (May 22)
Filter
Free / Premium
Streams
Clear
Choose Day